Myelofibrosis risk factors: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
Common risk factors in the development of myelofibrosis include: | Common risk factors in the development of myelofibrosis include: | ||
*'''Age''': Old age seem to be an important risk factor with individuals being in their 50s and 60s.<ref name="pmid15160918">{{cite journal |vauthors=Kreft A, Wiese B, Weiss M, Choritz H, Buhr T, Büsche G, Georgii A |title=Analysis of risk factors of the evolution of myelofibrosis in pre-fibrotic chronic idiopathic myelofibrosis: a retrospective study based on follow up biopsies of 70 patients by using the RECPAM method |journal=Leuk. Lymphoma |volume=45 |issue=3 |pages=553–9 |date=March 2004 |pmid=15160918 |doi= |url=}}</ref> | *'''Age''': Old age seem to be an important risk factor with individuals being in their 50s and 60s.<ref name="pmid15160918">{{cite journal |vauthors=Kreft A, Wiese B, Weiss M, Choritz H, Buhr T, Büsche G, Georgii A |title=Analysis of risk factors of the evolution of myelofibrosis in pre-fibrotic chronic idiopathic myelofibrosis: a retrospective study based on follow up biopsies of 70 patients by using the RECPAM method |journal=Leuk. Lymphoma |volume=45 |issue=3 |pages=553–9 |date=March 2004 |pmid=15160918 |doi= |url=}}</ref> | ||
*'''Other myeloproliferative disorder''': Other myeloproliferative disorders such as polycythemia vera and essential thrombocythemia, may pave the way for the development of myelofibrosis.<ref name="pmid23787440">{{cite journal |vauthors=Boiocchi L, Mathew S, Gianelli U, Iurlo A, Radice T, Barouk-Fox S, Knowles DM, Orazi A |title=Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage |journal=Mod. Pathol. |volume=26 |issue=12 |pages=1577–85 |date=December 2013 |pmid=23787440 |doi=10.1038/modpathol.2013.109 |url=}}</ref><ref name="pmid28561069">{{cite journal |vauthors=Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM |title=A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis |journal=Leukemia |volume=31 |issue=12 |pages=2726–2731 |date=December 2017 |pmid=28561069 |doi=10.1038/leu.2017.169 |url=}}</ref><ref name="pmid28601551">{{cite journal |vauthors=Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S |title=Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis |journal=Leuk. Res. |volume=59 |issue= |pages=110–116 |date=August 2017 |pmid=28601551 |pmc=5573611 |doi=10.1016/j.leukres.2017.06.001 |url=}}</ref> | *'''Other myeloproliferative disorder''': Other myeloproliferative disorders such as polycythemia vera and essential thrombocythemia, may pave the way for the development of myelofibrosis.<ref name="pmid23787440">{{cite journal |vauthors=Boiocchi L, Mathew S, Gianelli U, Iurlo A, Radice T, Barouk-Fox S, Knowles DM, Orazi A |title=Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage |journal=Mod. Pathol. |volume=26 |issue=12 |pages=1577–85 |date=December 2013 |pmid=23787440 |doi=10.1038/modpathol.2013.109 |url=}}</ref><ref name="pmid28561069">{{cite journal |vauthors=Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM |title=A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis |journal=Leukemia |volume=31 |issue=12 |pages=2726–2731 |date=December 2017 |pmid=28561069 |doi=10.1038/leu.2017.169 |url=}}</ref><ref name="pmid28601551">{{cite journal |vauthors=Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S |title=Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis |journal=Leuk. Res. |volume=59 |issue= |pages=110–116 |date=August 2017 |pmid=28601551 |pmc=5573611 |doi=10.1016/j.leukres.2017.06.001 |url=}}</ref><ref name="pmid29713873">{{cite journal |vauthors=Passamonti F, Mora B, Barraco D, Maffioli M |title=Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis |journal=Curr Hematol Malig Rep |volume=13 |issue=3 |pages=173–182 |date=June 2018 |pmid=29713873 |doi=10.1007/s11899-018-0453-y |url=}}</ref><ref name="pmid28674362">{{cite journal |vauthors=Ikeda K, Ueda K, Sano T, Ogawa K, Ikezoe T, Hashimoto Y, Morishita S, Komatsu N, Ohto H, Takeishi Y |title=The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation |journal=Intern. Med. |volume=56 |issue=13 |pages=1705–1710 |date=2017 |pmid=28674362 |pmc=5519475 |doi=10.2169/internalmedicine.56.7871 |url=}}</ref><ref name="pmid28561069">{{cite journal |vauthors=Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM |title=A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis |journal=Leukemia |volume=31 |issue=12 |pages=2726–2731 |date=December 2017 |pmid=28561069 |doi=10.1038/leu.2017.169 |url=}}</ref><ref name="pmid28464892">{{cite journal |vauthors=Li B, Gale RP, Xu Z, Qin T, Song Z, Zhang P, Bai J, Zhang L, Zhang Y, Liu J, Huang G, Xiao Z |title=Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis |journal=J Hematol Oncol |volume=10 |issue=1 |pages=99 |date=May 2017 |pmid=28464892 |pmc=5414291 |doi=10.1186/s13045-017-0472-5 |url=}}</ref> | ||
*'''Malignancies''': Primary malignancies of different body parts and systems can also act as a significant risk factor myelofibrosis development.<ref name="pmid28781273">{{cite journal |vauthors=Sakatoku K, Takeoka Y, Araki T, Miura A, Fujitani Y, Yamamura R, Miyagi Y, Senzaki H, Ohta K |title=Lymphocyte-depleted classical Hodgkin lymphoma accompanied by myelofibrosis |language=Japanese |journal=Rinsho Ketsueki |volume=58 |issue=7 |pages=772–775 |date=2017 |pmid=28781273 |doi=10.11406/rinketsu.58.772 |url=}}</ref><ref name="pmid26622707">{{cite journal |vauthors=Fu R, Yu H, Wu YH, Liu H, Shao ZH |title=Hodgkin's lymphoma associated with myelofibrosis: A case report |journal=Oncol Lett |volume=10 |issue=3 |pages=1551–1554 |date=September 2015 |pmid=26622707 |pmc=4533276 |doi=10.3892/ol.2015.3438 |url=}}</ref> | |||
*'''Radiation exposure''': Individuals exposed to high levels of [[radiation]] (e.g. Thorotrast) have an increased risk of myelofibrosis. | *'''Radiation exposure''': Individuals exposed to high levels of [[radiation]] (e.g. Thorotrast) have an increased risk of myelofibrosis. | ||
*'''Chemicals''': Industrial chemicals, such as toluene and benzene, may have an increased risk of developing myelofibrosis. | *'''Chemicals''': Industrial chemicals, such as toluene and benzene, may have an increased risk of developing myelofibrosis. | ||
Revision as of 21:12, 19 November 2018
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis risk factors On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis risk factors |
|
Risk calculators and risk factors for Myelofibrosis risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Myelofibrosis is a rare disorder and its common risk factors may be age, other myeloproliferative disorders, radiation, or industrial chemical exposure.
Risk Factors
Common risk factors in the development of myelofibrosis include:
- Age: Old age seem to be an important risk factor with individuals being in their 50s and 60s.[1]
- Other myeloproliferative disorder: Other myeloproliferative disorders such as polycythemia vera and essential thrombocythemia, may pave the way for the development of myelofibrosis.[2][3][4][5][6][3][7]
- Malignancies: Primary malignancies of different body parts and systems can also act as a significant risk factor myelofibrosis development.[8][9]
- Radiation exposure: Individuals exposed to high levels of radiation (e.g. Thorotrast) have an increased risk of myelofibrosis.
- Chemicals: Industrial chemicals, such as toluene and benzene, may have an increased risk of developing myelofibrosis.
References
- ↑ Kreft A, Wiese B, Weiss M, Choritz H, Buhr T, Büsche G, Georgii A (March 2004). "Analysis of risk factors of the evolution of myelofibrosis in pre-fibrotic chronic idiopathic myelofibrosis: a retrospective study based on follow up biopsies of 70 patients by using the RECPAM method". Leuk. Lymphoma. 45 (3): 553–9. PMID 15160918.
- ↑ Boiocchi L, Mathew S, Gianelli U, Iurlo A, Radice T, Barouk-Fox S, Knowles DM, Orazi A (December 2013). "Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage". Mod. Pathol. 26 (12): 1577–85. doi:10.1038/modpathol.2013.109. PMID 23787440.
- ↑ 3.0 3.1 Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM (December 2017). "A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis". Leukemia. 31 (12): 2726–2731. doi:10.1038/leu.2017.169. PMID 28561069.
- ↑ Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S (August 2017). "Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis". Leuk. Res. 59: 110–116. doi:10.1016/j.leukres.2017.06.001. PMC 5573611. PMID 28601551.
- ↑ Passamonti F, Mora B, Barraco D, Maffioli M (June 2018). "Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis". Curr Hematol Malig Rep. 13 (3): 173–182. doi:10.1007/s11899-018-0453-y. PMID 29713873.
- ↑ Ikeda K, Ueda K, Sano T, Ogawa K, Ikezoe T, Hashimoto Y, Morishita S, Komatsu N, Ohto H, Takeishi Y (2017). "The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation". Intern. Med. 56 (13): 1705–1710. doi:10.2169/internalmedicine.56.7871. PMC 5519475. PMID 28674362.
- ↑ Li B, Gale RP, Xu Z, Qin T, Song Z, Zhang P, Bai J, Zhang L, Zhang Y, Liu J, Huang G, Xiao Z (May 2017). "Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis". J Hematol Oncol. 10 (1): 99. doi:10.1186/s13045-017-0472-5. PMC 5414291. PMID 28464892.
- ↑ Sakatoku K, Takeoka Y, Araki T, Miura A, Fujitani Y, Yamamura R, Miyagi Y, Senzaki H, Ohta K (2017). "Lymphocyte-depleted classical Hodgkin lymphoma accompanied by myelofibrosis". Rinsho Ketsueki (in Japanese). 58 (7): 772–775. doi:10.11406/rinketsu.58.772. PMID 28781273.
- ↑ Fu R, Yu H, Wu YH, Liu H, Shao ZH (September 2015). "Hodgkin's lymphoma associated with myelofibrosis: A case report". Oncol Lett. 10 (3): 1551–1554. doi:10.3892/ol.2015.3438. PMC 4533276. PMID 26622707.